Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 14/20 | 0.38 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17081994 | 0.85 | MALT1 (0.41) | EGLN1MALT1DDB1CRBNHCRTR2 | |
| SCHEMBL549480 | 0.85 | MALT1 (0.41) | EGLN1MALT1DDB1CRBNHCRTR2 | |
| SCHEMBL17081990 | 0.82 | EGLN1 (0.40) | EGLN1MALT1DDB1CRBNHCRTR2 | |
| SCHEMBL550677 | 0.82 | EGLN1 (0.40) | EGLN1MALT1DDB1CRBNHCRTR2 | |
| SCHEMBL4570053 | 0.79 | MALT1 (0.52) | EGLN1MALT1 | |
| SCHEMBL4570051 | 0.77 | HSD11B1 (0.41) | EGLN1MALT1 | |
| SCHEMBL17081991 | 0.75 | EGLN1 (0.38) | EGLN1MALT1DDB1CRBNHCRTR2 | |
| SCHEMBL549652 | 0.75 | EGLN1 (0.38) | EGLN1MALT1DDB1CRBNHCRTR2 | |
| SCHEMBL550273 | 0.74 | HSD11B1 (0.44) | EGLN1MALT1 | |
| SCHEMBL17082059 | 0.74 | HSD11B1 (0.44) | EGLN1MALT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122858-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2012-05-17 | — | — | US | disclosed |
| US-8110581-B2 | Lactam compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2012-02-07 | — | — | US | disclosed |
| US-20090291946-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291946-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | HSD11B1, HSD11B2, HSD17B1 | EGLN1 2089/4885MALT1 201/4885DDB1 3426/4885 |
| US-20120122858-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | HSD11B1, HSD11B2, HSD17B1 | EGLN1 2089/4885MALT1 201/4885DDB1 3426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.